Abstract
The use of combination chemotherapy and the introduction of new cytotoxic agents has resulted in therapeutic advances for patients with cancer. Unfortunately, even with the development of innovative multi-drug treatment regimens and the increasing availability of both autologous bone marrow transplantation (ABMT) and peripheral blood stem cell transplantation (PBSCT), the clinician lacks the necessary tools to successfully combat the progression of malignancy in the majority of patients. Furthermore, substantial morbidity and potential mortality is associated with the use of these aggressive treatment programs. New anti-tumor agents ideally should circumvent the two major limitations of current therapy: devastating nonspecific side effects and tumor cell resistance.KeywordsAcute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaSmall Cell Lung CancerMaximum Tolerate DoseAcute Myelogenous LeukemiaThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
